Key highlights
- The 200 mg cohort achieved a 70% mean reduction in PLA2R antibody levels by Week 12
- Five of thirteen patients or 38% in the low-dose cohort reached immunologic remission
- Initial 600 mg cohort data showed 98% peripheral B-cell suppression at Week 4
- A minimal change disease case study demonstrated a three-year steroid-free remission
- Pharmacokinetic analysis revealed two-fold faster drug clearance in proteinuric patients
Initial Phase 2 Efficacy and Safety
The Phase 2 PrisMN trial evaluating budoprutug in primary membranous nephropathy demonstrated a 70% mean reduction in PLA2R antibody levels at Week 12 within the 200 mg cohort. Five out of thirteen patients achieved immunologic remission during this period. Preliminary data from the 600 mg cohort indicated deeper peripheral B-cell depletion, with 98% suppression at Week 4 compared to 74% in the lower-dose group. These findings, presented at the American Society of Nephrology Kidney Week 2026, suggest that higher dosages may offer enhanced efficacy by accounting for accelerated drug clearance observed in proteinuric patients. Most adverse events were categorized as mild to moderate, with no treatment-related serious adverse events reported.
Dose Escalation and Pharmacokinetics
A population pharmacokinetic analysis of approximately 120 subjects revealed that individuals with high proteinuria clear the antibody at least twice as fast as those without the condition. This clearance rate supports the current clinical strategy of evaluating higher dose levels to maintain therapeutic exposure. Beyond the primary trial, the company presented a case study of a patient with frequently relapsing minimal change disease (MCD) who maintained a three-year steroid-free remission after a single 100 mg dose. Consequently, enrollment has commenced for a 1000 mg cohort to further optimize the therapeutic window, with additional PrisMN trial readouts anticipated in 2027.
Strategic Clinical Outlook
“These initial PrisMN results build on our Phase 1b findings, demonstrating early immunologic activity at 200 mg and the potential for increased activity at higher doses.”
Business and Financial Context
Climb Bio is a clinical-stage biotechnology firm concentrated on developing monoclonal antibodies for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 antibody designed to deplete B-cells responsible for autoimmune responses. The company is also advancing CLYM116 for IgA nephropathy, with Phase 2 results expected in the first half of 2027. Following a $110 million private placement and a $100 million at-the-market offering agreement earlier this year, the company reported cash and marketable securities of $239.2 million. Management anticipates this capital will fund operations into the second half of 2028, covering the completion of ongoing renal clinical programs.
Down 2.5% since our story on 26 Oct: $10.19 when we broke it → $9.94 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $9.73 |
|---|---|
| 20 Oct | $10.80 |
| 21 Oct | $10.87 |
| 22 Oct | $10.54 |
| 23 Oct | $10.19 |
| 26 Oct | $8.81 |
| 27 Oct | $9.57 |
| 28 Oct | $10.12 |
| 29 Oct | $10.33 |
| 30 Oct | $10.25 |
| 2 Nov | $9.74 |
| 3 Nov | $9.75 |
| 4 Nov | $9.33 |
| 5 Nov | $8.87 |
| 6 Nov | $10.29 |
| 9 Nov | $11.01 |
| 10 Nov | $11.74 |
| 11 Nov | $12.25 |
| 12 Nov | $10.87 |
| 13 Nov | $10.36 |
| 16 Nov | $9.94 |
| Date | Announcement | Amount |
|---|---|---|
| 24 Oct 2026 | Initial Phase 2 PrisMN trial data for budoprutug in primary membranous nephropathy presented at ASN Kidney Week 2026Source: globenewswire.com | – |
| 23 Oct 2026 | Phase 1 healthy volunteer clinical data for CLYM116/MIL116 in IgA nephropathy presented with Mabworks at ASN Kidney Week 2026Source: ir.climbbio.com | – |
| 03 Sep 2026 | Positive initial Phase 1 clinical trial data and development plans announced for CLYM116 in IgA nephropathySource: globenewswire.com | – |
| 06 Aug 2026 | Second quarter 2026 financial results and business updates reportedSource: globenewswire.com | – |
| 12 Jun 2026 | Open Market Sale Agreement entered with Jefferies LLC for an at-the-market common stock offeringSource: SEC filing | $100.0 Million |
| 28 Apr 2026 | Securities purchase agreement entered for a private placement of common stock and pre-funded warrantsSource: SEC filing | $110.0 Million |
Management commentary
“These initial PrisMN results build on our Phase 1b findings, demonstrating early immunologic activity at 200 mg and the potential for increased activity at higher doses.”
“Current treatment strategies fail to induce complete remission in most patients with pMN, underscoring the need for more effective treatments.”
| Share price | $10.19 |
|---|---|
| Market cap | $585M |
| 1-month price change | -18.61% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Climb Bio, Inc. announcing initial Phase 2 clinical data for budoprutug in renal indications.
Track Climb Bio, Inc. live
Get the next Climb Bio, Inc. SEC filing seconds after it lands.